Evidence map›Paper›PMID 28871441›Full record

ReviewMedizinische Klinik, Intensivmedizin und Notfallmedizin2019

International registry on the use of the CytoSorb® adsorber in ICU patients : Study protocol and preliminary results.

S Friesecke, K Träger, G A Schittek, Z Molnar, F Bach, K Kogelmann, R Bogdanski, A Weyland, A Nierhaus, F Nestler and 16 more

7 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02312024 completednot on this map

International Registry on the Use of the CytoSorb®-Adsorber in ICU Patients

Typeobservational_patient_registrySponsorJena University HospitalRan2015 to 2021Enrolled1,434ConditionsSepsis, Need of Cardiac SurgeryArmsUse of CytoSorb adsorber
NCT03807414 active not recruitingnot on this map

Development of a Web-based Multicenter Registry on the Use of oXiris Membrane for Extracorporeal Blood Purification Therapies in Critically Ill Patients

TypeobservationalSponsorCareggi HospitalRan2019 to 2025Enrolled270ConditionsCritical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response SyndromeArmsoXiris
NCT04033224 recruitingnot on this map

Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure: a Multicenter Prospective Observational Registry

Typeobservational_patient_registrySponsorCareggi HospitalRan2019 to 2025Enrolled1,000ConditionsCritical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response SyndromeArmsCommercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
NCT04580680 recruitingnot on this mapstarted 2020, after this paper: background citation

Extracorporeal Blood Purification Therapy in Critically Ill Patients: an Interactive,Web-based,Multicenter,Observational Prospective Registry

Typeobservational_patient_registrySponsorCareggi HospitalRan2020 to 2025Enrolled1,000ConditionsCritical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response SyndromeArmsCommercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
NCT04742764 phase3suspendednot on this mapstarted 2024, after this paper: background citation

Dosing of Extracorporeal Cytokine Removal In Septic Shock (DECRISS): a Prospective, Randomized, Multicenter Clinical Trial

TypeinterventionalSponsorUniversity of PecsRan2024 to 2027Enrolled135ConditionsSeptic ShockArmsStandard medical therapy, Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours, Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours
NCT05042622 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Innovative Solutions to Organ-substituting Technologies in the Treatment of Heart and Pulmonary Failure

TypeinterventionalSponsorNational Research Center for Cardiac Surgery, KazakhstanRan2021 to 2023Enrolled90ConditionsAcute Respiratory Distress Syndrome, Septic Shock, SepsisArmsCytokine adsorber filter, Extracorporeal hemoperfusion cartridge
NCT05090930 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Development of Innovative Technologies for the Treatment of Pulmonary and Heart Failure to Prolong Human's Life

TypeinterventionalSponsorNational Research Center for Cardiac Surgery, KazakhstanRan2021 to 2023Enrolled100ConditionsCardiogenic Shock, Ventricular Arrythmia, Cardiac Arrest With Successful Resuscitation, SepsisArmsHA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Retrospective evaluation of efficacy of CytoSorbWorld journal of critical care medicine · 2025
    Article
  8. Review
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

S FrieseckeKlinik und Poliklinik für Innere Medizin B, Universitätsmedizin Greifswald, Greifswald, Germany.
K TrägerKardioanästhesiologie, Universitätsklinikum Ulm, Ulm, Germany.
G A SchittekKlinik für Anästhesiologie, Intensivtherapie und Palliativmedizin, Carl-Thiem-Klinikum Cottbus, Cottbus, Germany.
Z MolnarDepartment of Anesthesiology and Intensive Care, University of Szeged, Szeged, Hungary.
F BachKlinik für Anästhesiologie, Intensiv‑, Notfallmedizin, Transfusionsmedizin und Schmerztherapie, Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany.
K KogelmannKlinik für Anästhesiologie und Intensivmedizin, Hans-Susemihl-Krankenhaus gGmbH, Emden, Germany.
R BogdanskiKlinik für Anästhesiologie, AG Hämodynamik, Klinikum rechts der Isar TU München, München, Germany.
A WeylandUniversitätsklinik für Anästhesiologie/Intensiv‑/Notfallmedizin/Schmerztherapie, Klinikum Oldenburg gGmbH, Carl von Ossietzky Universität, Oldenburg, Germany.
A NierhausKlinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
F NestlerAnästhesie und Intensivmedizin, Kliniken Erlabrunn gGmbH, Breitenbrunn, Germany.
D OlboeterAnästhesie und Intensivmedizin, Krankenhaus Herzberg, Elbe-Elster-Klinikum GmbH, Herzberg, Germany.
D TomescuFundeni Clinical Institute, Bucharest, Romania.
D JacobKlinik für Allgemein‑, Viszeral- und Gefäßchirurgie, Universitätsklinikum Magdeburg, Magdeburg, Germany.
H HaakeKlinik für Kardiologie und Intensivmedizin, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.
E GrigoryevInstitute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation.
M NitschKlinik für Anästhesie, Intensiv‑, Notfallmedizin und Schmerztherapie, Krankenhaus St. Elisabeth und St. Barbara Halle, Halle, Germany.
A BaumannKlinik für Anästhesie, Intensiv‑, Palliativ- und Schmerzmedizin, Berufsgenossensch. Uniklinik Bergmannsheil, Bochum, Germany.
M QuintelZentrum Anästhesiologie, Rettungs-und Intensivmedizin, Universitätsklinikum Göttingen, Göttingen, Germany.
M SchottKlinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Klinikum Region Hannover Nordstadt, Hannover, Germany.
J T KielsteinMedizinische Klinik V, Klinikum Braunschweig, Braunschweig, Germany.
A Meier-HellmannAnästhesie, Intensivmedizin und Schmerztherapie, HELIOS Klinikums Erfurt, Erfurt, Germany.
F BornHerzchirurgische Klinik und Poliklinik, LMU München, München, Germany.
U SchumacherCenter for Clinical Studies Jena (ZKS), Jena, Germany.
M SingerIntensive Care Medicine, University College London, London, UK.
J KellumDepartment of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA.
F M BrunkhorstCenter for Clinical Studies Jena (ZKS), Jena, Germany. Frank.Brunkhorst@med.uni-jena.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of this clinical registry is to record the use of CytoSorb® adsorber device in critically ill patients under real-life conditions.

methodsThe registry records all relevant information in the course of product use, e. g., diagnosis, comorbidities, course of the condition, treatment, concomitant medication, clinical laboratory parameters, and outcome (ClinicalTrials.gov Identifier: NCT02312024). Primary endpoint is in-hospital mortality as compared to the mortality predicted by the APACHE II and SAPS II score, respectively.

resultsAs of January 30, 2017, 130 centers from 22 countries were participating. Data available from the start of the registry on May 18, 2015 to November 24, 2016 (122 centers; 22 countries) were analyzed, of whom 20 centers from four countries provided data for a total of 198 patients (mean age 60.3 ± 15.1 years, 135 men [68.2%]). In all, 192 (97.0%) had 1 to 5 Cytosorb® adsorber applications. Sepsis was the most common indication for CytoSorb® treatment (135 patients). Mean APACHE II score in this group was 33.1 ± 8.4 [range 15-52] with a predicted risk of death of 78%, whereas the observed mortality was 65%. There were no significant decreases in the SOFA scores after treatment (17.2 ± 4.8 [3-24]). However interleukin-6 levels were markedly reduced after treatment (median 5000 pg/ml before and 289 pg/ml after treatment, respectively).

conclusionsThis third interim report demonstrates the feasibility of the registry with excellent data quality and completeness from 20 study centers. The results must be interpreted with caution, since the numbers are still small; however the disease severity is remarkably high and suggests that adsorber treatment might be used as an ultimate treatment in life-threatening situations. There were no device-associated side effects.

Indexed as

Critical IllnessHospital MortalityIntensive Care UnitsSimplified Acute Physiology ScoreAgedAPACHEExtracorporeal CirculationHumansMaleMiddle AgedRegistriesCytokinesExtracorporeal life supportInflammationIntensive care unitsSepsis

Identifiers

PMID28871441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.